BCMA-GPRC5D CAR-T cells is named as a drug or biological intervention in 2 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include Shenzhen University General Hospital (1) and Essen Biotech (1). Registered phase: Phase 1/2. Conditions studied include Multiple Myeloma in Relapse; Multiple Myeloma; Multiple Myeloma Progression.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06644443 | BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma (ClinicalTrials.gov ↗) Multiple Myeloma in Relapse |
Phase 1/2 | Recruiting |
| NCT07032129 | Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma (ClinicalTrials.gov ↗) Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma Progression |
Phase 1/2 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Multiple Myeloma in Relapse | 2 |
| Multiple Myeloma | 1 |
| Multiple Myeloma Progression | 1 |
| Multiple Myeloma, Refractory | 1 |
| Lead sponsor | Trials |
|---|---|
| Shenzhen University General Hospital | 1 |
| Essen Biotech | 1 |
| Register | BCMA-GPRC5D CAR-T cells trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how BCMA-GPRC5D CAR-T cells works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists BCMA-GPRC5D CAR-T cells (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.